Overdiagnosis of bone fragility in the quest to prevent hip fracture

Despite widespread endorsement, Teppo Järvinen and colleagues argue that evidence for stratifying risk of fracture and subsequent drug therapy to prevent hip fracture is insufficient to warrant our current approach

[1]  P. Kannus,et al.  Osteoporosis and vertebral fractures: a newly discovered epidemic or just an example of overdiagnosis and disease mongering? , 2017 .

[2]  S. Perera,et al.  Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. , 2015, JAMA internal medicine.

[3]  I. Redlund‐Johnell,et al.  Low clinical relevance of a prevalent vertebral fracture in elderly men--the MrOs Sweden study. , 2015, The spine journal : official journal of the North American Spine Society.

[4]  K. Michaëlsson,et al.  Risk of atypical femoral fracture during and after bisphosphonate use , 2015, Acta orthopaedica.

[5]  J. Cauley,et al.  Secular Trends in Hip Fractures Worldwide: Opposing Trends East Versus West , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  I. Reid,et al.  Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues? , 2014, Osteoporosis International.

[7]  I. Reid,et al.  The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. , 2014, The lancet. Diabetes & endocrinology.

[8]  Gary S Collins,et al.  Conflicts at the heart of the FRAX tool , 2014, Canadian Medical Association Journal.

[9]  I. Reid.  Should We Prescribe Calcium Supplements For Osteoporosis Prevention? , 2014, Journal of bone metabolism.

[10]  Per Aspenberg,et al.  Denosumab and atypical femoral fractures , 2014, Acta orthopaedica.

[11]  Marie-Aline Charles,et al.  The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials , 2013, British Journal of Sports Medicine.

[12]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[13]  J. Kanis,et al.  Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. , 2013, Maturitas.

[14]  P. Kannus,et al.  Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010 , 2013, Osteoporosis International.

[15]  Gary S Collins,et al.  Fracture Risk Assessment: State of the Art, Methodologically Unsound, or Poorly Reported? , 2012, Current Osteoporosis Reports.

[16]  Marcea Whitaker,et al.  Bisphosphonates for osteoporosis--where do we go from here? , 2012, The New England journal of medicine.

[17]  I. Reid.  Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies , 2011, Skeletal Radiology.

[18]  C. Cooper,et al.  Clinicians need to treat underlying osteoporosis , 2011, BMJ : British Medical Journal.

[19]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  C. Cooper,et al.  Interpretation and use of FRAX in clinical practice , 2011, Osteoporosis International.

[21]  P. Kannus,et al.  The true cost of pharmacological disease prevention , 2011, BMJ : British Medical Journal.

[22]  A. Avenell,et al.  Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis , 2011, BMJ : British Medical Journal.

[23]  R. Eastell,et al.  Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. , 2010, The Journal of clinical endocrinology and metabolism.

[24]  S. Boonen,et al.  Efficacy and Safety of a Once‐Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older , 2010, Journal of the American Geriatrics Society.

[25]  A. LaCroix,et al.  Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe , 2010, BMJ : British Medical Journal.

[26]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[27]  S. Cummings,et al.  Estimates of the Proportion of Older White Women Who Would Be Recommended for Pharmacologic Treatment by the New U.S. National Osteoporosis Foundation Guidelines , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  J. Kanis,et al.  Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK , 2008, Osteoporosis International.

[29]  L. Melton,et al.  Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.

[30]  G. Guyatt,et al.  Drugs for pre-osteoporosis: prevention or disease mongering? , 2008, BMJ : British Medical Journal.

[31]  Ari Heinonen,et al.  Shifting the focus in fracture prevention from osteoporosis to falls , 2008, BMJ : British Medical Journal.

[32]  Lisa M. Schwartz,et al.  Implications of expanding disease definitions: the case of osteoporosis. , 2007, Health affairs.

[33]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[34]  K. Michaëlsson,et al.  Leisure Physical Activity and the Risk of Fracture in Men , 2007, PLoS medicine.

[35]  Pekka Kannus,et al.  Bone Quality: An Empty Term , 2007, PLoS medicine.

[36]  J. Pasco,et al.  Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? , 2006, Bone.

[37]  K. Michaëlsson,et al.  Smoking and the Risk of Fracture in Older Men , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  A. Silman,et al.  Predictive Value of BMD for Hip and Other Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  J. Reginster,et al.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.

[40]  H. Kroger,et al.  Smoking and fracture risk: a meta-analysis , 2005, Osteoporosis International.

[41]  S. Cummings,et al.  BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  M. Tinetti.  Clinical practice. Preventing falls in elderly persons. , 2003, The New England journal of medicine.

[43]  W. Willett,et al.  Walking and leisure-time activity and risk of hip fracture in postmenopausal women. , 2002, JAMA.

[44]  P. Kannus,et al.  Why Is the Age‐Standardized Incidence of Low‐Trauma Fractures Rising in Many Elderly Populations? , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[46]  O Johnell,et al.  Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. , 2000, Bone.

[47]  Christianna S. Williams,et al.  Falls, injuries due to falls, and the risk of admission to a nursing home. , 1997, The New England journal of medicine.

[48]  M. Hochberg.  Bisphosphonates in the treatment of osteoporosis. , 1997, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[49]  O Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. , 1996, BMJ.

[50]  J. Kanis,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.

[51]  S. Cummings,et al.  Results of bone densitometry affect women's decisions about taking measures to prevent fractures. , 1992, Annals of internal medicine.

[52]  N J Wald,et al.  Strategies for prevention of osteoporosis and hip fracture. , 1991, BMJ.

[53]  O. Törring,et al.  Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[54]  J. Gilliland,et al.  Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces , 2013, Osteoporosis International.

[55]  M. Swiontkowski.  Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis , 2011 .

[56]  G. Oster,et al.  Effectiveness of bisphosphonate therapy in a community setting. , 2009, Bone.

[57]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.

[58]  N. Pedersen,et al.  American Journal of Epidemiology Original Contribution Simply Ask Them about Their Balance—future Fracture Risk in a Nationwide Cohort Study of Twins , 2022 .